Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicinal composition containing sodium ozagrel compound

A technology of sodium ozagrel and its composition, which is applied in the field of freeze-dried powder injection of sodium ozagrel and its preparation, can solve the problems of inconvenient use and unsatisfactory dissolution speed, and achieve convenient use, rapid dissolution and stability Good results

Active Publication Date: 2013-03-27
姚云
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Some products have unsatisfactory dissolution speed during clinical use, which causes inconvenient use. This invention provides a new prescription and preparation method, so that the medicine will not turn yellow when stored for a long time, and at the same time, the dissolution speed is improved.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition containing sodium ozagrel compound
  • Medicinal composition containing sodium ozagrel compound
  • Medicinal composition containing sodium ozagrel compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0061] Ozagrel sodium 20g;

[0062] Mannitol 150g;

[0063] Calcium EDTA 2g;

[0064] Glucose 1.5g,

[0065] 2000ml of disodium hydrogen citrate and trisodium citrate buffer solution with a molar ratio of 1:4;

[0066] Preparation

[0067] (1) Weigh the raw and auxiliary materials according to the prescription quantity

[0068] (2) Add mannitol, EDTA calcium, and glucose to 1000ml of disodium hydrogen citrate and trisodium citrate buffer solution with a molar ratio of 1:4, and stir to dissolve.

[0069] (3) Add the prescribed amount of sodium ozagrel into the solution and stir to dissolve completely. Add disodium hydrogen citrate and trisodium citrate buffer with a molar ratio of 1:4 to the full amount, and stir to mix evenly.

[0070] (4) Measure the pH of the solution to be 7.0.

[0071] (5) Fine filter with a 0.2 μm microporous membrane to check the clarity of the solution.

[0072] (6) According to the measurement results, fill the liquid medicine into a vial with ...

Embodiment 2

[0076] Ozagrel sodium 20g;

[0077] Mannitol 100g;

[0078] Calcium EDTA 1g;

[0079] Glucose 1g,

[0080] 2000ml of disodium hydrogen citrate and trisodium citrate buffer solution with a molar ratio of 1:4;

[0081] Preparation

[0082] (1) Weigh the raw and auxiliary materials according to the prescription quantity

[0083] (2) Add mannitol, EDTA calcium, and glucose to 1000ml of disodium hydrogen citrate and trisodium citrate buffer solution with a molar ratio of 1:4, and stir to dissolve.

[0084] (3) Add the prescribed amount of sodium ozagrel into the solution and stir to dissolve completely. Add disodium hydrogen citrate and trisodium citrate buffer with a molar ratio of 1:4 to the full amount, and stir to mix evenly.

[0085] (4) Measure the pH value of the solution, which is 7.0.

[0086] (5) Fine filter with a 0.2 μm microporous membrane to check the clarity of the solution.

[0087] (6) According to the measurement results, fill the liquid medicine into a vial...

Embodiment 3

[0091] Ozagrel sodium 20g;

[0092] Mannitol 200g;

[0093] Calcium EDTA 3g;

[0094] Glucose 2g,

[0095] 2000ml of disodium hydrogen citrate and trisodium citrate buffer solution with a molar ratio of 1:4;

[0096] Preparation

[0097] (1) Weigh the raw and auxiliary materials according to the prescription quantity

[0098] (2) Add mannitol, EDTA calcium, and glucose to 1000ml of disodium hydrogen citrate and trisodium citrate buffer solution with a molar ratio of 1:4, and stir to dissolve.

[0099] (3) Add the prescribed amount of sodium ozagrel into the solution and stir to dissolve completely. Add disodium hydrogen citrate and trisodium citrate buffer with a molar ratio of 1:4 to the full amount, and stir to mix evenly.

[0100] (4) Measure the pH value of the solution, which is 7.0.

[0101] (5) Fine filter with a 0.2 μm microporous membrane to check the clarity of the solution.

[0102] (6) According to the measurement results, fill the liquid medicine into a vi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a medicinal composition containing sodium ozagrel, and the medicinal composition is a freeze-dried injection. Each 1,000 injections are prepared from the following components: 20g of sodium ozagrel, 100 to 200g of mannitol, 1 to 3g of ethylene diamine tetraacetic acid (EDTA) calcium, 1 to 2g of glucose, and 2,000ml of buffer solution of disodium hydrogen citrate and trisodium citrate at a mole ratio of 1: 4, wherein the pH value of the injection is 7.0.

Description

technical field [0001] The invention relates to a freeze-dried powder injection of ozagrel sodium and a preparation method thereof, belonging to the field of medicine. Background technique [0002] Ozagrel, English name: Ozagrel, chemical structural formula is as follows: [0003] [0004] Ozagrel is a thromboxane synthase inhibitor, which can inhibit the production of TXA2, so it has anti-platelet aggregation and vasodilator effects. Animal experiments showed that intravenous administration can reduce plasma TXB2 level, Keto-PGF12 / TXB2 ratio decreased, inhibit platelet aggregation caused by different inducers, and prevent cerebral infarction caused by middle cerebral artery in rats. [0005] After intravenous infusion of ozagrel sodium, the plasma concentration-time curve conformed to the two-compartment open model, t1 / 2β was 1.22±0.44h, Vd was 2.32±0.62L / kg, and AUC was 0.47±0.08μg·hr / ml. Cl is 3.25±0.82L / h / kg, the longest half-life of the subject is 1.93h, the blood ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/19A61K31/4174A61K47/26A61P7/02
Inventor 姚云
Owner 姚云
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com